SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Schedule of research and development expenses) (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Supplementary Financial Statement Information [Abstract] | ||||
| Payroll and related expenses | $ 1,026 | $ 763 | $ 2,083 | $ 1,687 |
| Clinical and preclinical trials expenses | 1,590 | 1,850 | 1,992 | 3,660 |
| Professional consulting and subcontracted work | 797 | 1,656 | 1,819 | 4,722 |
| Supplier-led manufacturing development | 0 | 0 | 0 | 2,749 |
| Other | 306 | 377 | 611 | 671 |
| Total Research and development expenses | $ 3,719 | $ 4,646 | $ 6,505 | $ 13,489 |
| X | ||||||||||
- Definition Represents the amount of clinical and preclinical trials expenses. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Information about supplier-led manufacturing development. No definition available.
|
| X | ||||||||||
- Definition Amount of expense classified as other. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of labor-related expenses classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for professional and contracted services. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|